{"id":"https://openalex.org/W2954987754","doi":"https://doi.org/10.1158/1538-7445.am2019-ct161","title":"Abstract CT161: A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)","display_name":"Abstract CT161: A Phase II study of the polo-like kinase (PLK1) inhibitor onvansertib in combination with abiraterone (abi) and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)","publication_year":2019,"publication_date":"2019-07-01","ids":{"openalex":"https://openalex.org/W2954987754","doi":"https://doi.org/10.1158/1538-7445.am2019-ct161","mag":"2954987754"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2019-ct161","doi":"https://doi.org/10.1158/1538-7445.am2019-ct161","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-ct161","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031890333","display_name":"David Johnson Einstein","orcid":"https://orcid.org/0000-0001-9163-3281","observed_orcids":["https://orcid.org/0000-0001-9163-3281"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David J. Einstein","raw_affiliation_strings":["1Beth Israel Deaconess Medical Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Beth Israel Deaconess Medical Center, Boston, MA;","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073984828","display_name":"Atish Dipankar Choudhury","orcid":"https://orcid.org/0000-0001-9344-6631","observed_orcids":["https://orcid.org/0000-0001-9344-6631"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Atish Choudhury","raw_affiliation_strings":["2Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062120456","display_name":"Philip James Saylor","orcid":"https://orcid.org/0000-0003-4849-3695","observed_orcids":["https://orcid.org/0000-0003-4849-3695"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip Saylor","raw_affiliation_strings":["3Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033518868","display_name":"Lillian L. Werner","orcid":"https://orcid.org/0000-0002-9063-0457","observed_orcids":["https://orcid.org/0000-0002-9063-0457"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lillian Werner","raw_affiliation_strings":["2Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003109423","display_name":"Mark G. Erlander","orcid":"https://orcid.org/0000-0002-4231-7095","observed_orcids":["https://orcid.org/0000-0002-4231-7095"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Erlander","raw_affiliation_strings":["4Trovagene, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Trovagene, Inc., San Diego, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071752028","display_name":"Maya Ridinger","orcid":"https://orcid.org/0000-0001-5833-5573","observed_orcids":["https://orcid.org/0000-0001-5833-5573"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maya Ridinger","raw_affiliation_strings":["4Trovagene, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Trovagene, Inc., San Diego, CA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043769628","display_name":"Glenn J. Bubley","orcid":"https://orcid.org/0000-0002-3062-643X","observed_orcids":["https://orcid.org/0000-0002-3062-643X"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Glenn Bubley","raw_affiliation_strings":["1Beth Israel Deaconess Medical Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Beth Israel Deaconess Medical Center, Boston, MA;","institution_ids":["https://openalex.org/I1316535847"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"79","issue":"13_Supplement","first_page":"CT161","last_page":"CT161"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/onvansertib","display_name":"onvansertib","score":0.9829999804496765},{"id":"https://openalex.org/keywords/plk1-inhibitors","display_name":"PLK1 inhibitors","score":0.921999990940094},{"id":"https://openalex.org/keywords/abiraterone-acetate","display_name":"abiraterone","score":0.9660000205039978},{"id":"https://openalex.org/keywords/prednisone","display_name":"prednisone","score":0.9670000076293945},{"id":"https://openalex.org/keywords/metastatic-castration-resistant-prostate-cancer","display_name":"metastatic castration-resistant prostate cancer","score":0.9909999966621399},{"id":"https://openalex.org/keywords/abiraterone-resistance","display_name":"abiraterone resistance","score":0.8920000195503235},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8769999742507935},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.6439999938011169},{"id":"https://openalex.org/keywords/prostate-specific-antigen","display_name":"prostate-specific antigen","score":0.6299999952316284},{"id":"https://openalex.org/keywords/circulating-tumor-cells","display_name":"circulating tumor cells","score":0.8379999995231628},{"id":"https://openalex.org/keywords/circulating-tumor-dna","display_name":"circulating tumor DNA","score":0.875},{"id":"https://openalex.org/keywords/cell-cycle-regulation","display_name":"cell cycle regulation","score":0.5630000233650208},{"id":"https://openalex.org/keywords/oral-kinase-inhibitor","display_name":"oral kinase inhibitor","score":0.640999972820282},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.5659999847412109}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8614869117736816},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7931705713272095},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.7194346189498901},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5693060159683228},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4841102361679077},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.47100985050201416},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.45659977197647095}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2019-ct161","doi":"https://doi.org/10.1158/1538-7445.am2019-ct161","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2019-ct161","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4254638511","https://openalex.org/W2921425242","https://openalex.org/W4213218344","https://openalex.org/W4282959599","https://openalex.org/W2985416373","https://openalex.org/W3178188792","https://openalex.org/W4280529461","https://openalex.org/W2793096203","https://openalex.org/W4309593095","https://openalex.org/W2761902517"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"mCRPC":[2,137],"remains":[3],"a":[4,28,32,79,166,230,243],"leading":[5],"cause":[6],"of":[7,24,35,52,97,108,131,148,165,181,189,202,217,255,275,280,287,324,349],"cancer-related":[8],"deaths":[9],"worldwide.":[10],"Although":[11],"abi":[12,53,113,154,170],"increases":[13],"survival,":[14],"resistance":[15,140],"is":[16,31,39,66,103,210],"universal":[17],"and":[18,38,58,138,155,173,264,285,300,336],"generally":[19],"occurs":[20],"within":[21],"9-16":[22],"months":[23],"initiating":[25],"treatment.":[26,270],"PLK1,":[27],"serine/threonine":[29],"kinase,":[30],"master":[33],"regulator":[34],"cell-cycle":[36],"progression":[37,150],"highly":[40],"upregulated":[41],"in":[42,54,110,134,232,283,291,298,331,338],"prostate":[43,343],"cancer":[44,344],"following":[45],"castration.":[46],"PLK1":[47,281],"inhibition":[48,282],"enhances":[49],"the":[50,67,106,200,248,256,325,350],"efficacy":[51],"cell":[55],"line":[56],"models":[57],"patient-derived":[59],"tumor":[60,277,293,301],"xenografts.":[61],"Onvansertib":[62],"(PCM-075;":[63],"Trovagene,":[64],"Inc.)":[65],"first":[68,257],"orally":[69,161,172],"available":[70],"PLK1-specific":[71],"inhibitor.":[72],"In":[73],"Phase":[74,99,321],"I":[75],"testing,":[76],"onvansertib":[77,109,158,203,330],"demonstrated":[78],"manageable":[80],"safety":[81,187],"profile,":[82],"with":[83,112,136,157,177,204,212,333,340],"transient":[84],"hematologic":[85],"effects":[86,107],"as":[87,119,216,296],"its":[88],"most":[89],"prominent,":[90],"yet":[91],"reversible,":[92],"toxicity.":[93],"Methods:":[94],"The":[95,186],"goal":[96],"this":[98],"II":[100,322],"study":[101,132,249,323],"(NCT03414034)":[102],"to":[104,141,228,238],"observe":[105],"combination":[111,201,332],"+":[114],"prednisone":[115,337],"on":[116,152,162,242],"disease":[117,261],"control,":[118],"assessed":[120],"by":[121],"prostate-specific":[122],"antigen":[123],"(PSA)":[124],"decline":[125],"or":[126,183,196],"stabilization":[127],"after":[128],"12":[129],"weeks":[130],"treatment,":[133],"subjects":[135,191],"early":[139,252],"abi.":[142,205],"Patients":[143],"are":[144,267],"enrolled":[145,215],"at":[146],"time":[147,180],"PSA":[149,265],"while":[151],"standard":[153],"treated":[156],"(24":[159],"mg/m2":[160],"days":[163],"1-5":[164],"21-day":[167],"cycle)":[168],"plus":[169],"(administered":[171],"continuously":[174],"once":[175],"daily":[176],"prednisone)":[178],"until":[179],"radiographic":[182],"symptomatic":[184],"progression.":[185],"lead-in":[188],"3":[190],"showed":[192],"no":[193],"dose-limiting":[194],"toxicities":[195,198],"new":[197],"from":[199,235],"A":[206,320],"29-patient":[207],"expansion":[208],"phase":[209],"ongoing,":[211],"11":[213],"patients":[214,259,339],"January":[218],"2019.":[219],"With":[220],"32":[221],"patients,":[222],"there":[223],"will":[224,250],"be":[225],"90%":[226],"power":[227],"detect":[229],"change":[231],"disease-control":[233],"rate":[234],"10%":[236],"(null)":[237],"30%":[239],"(alternative).":[240],"Based":[241],"Simon\u2019s":[244],"two-stage":[245],"optimal":[246],"design,":[247],"terminate":[251],"if":[253],"<2":[254],"13":[258],"achieve":[260],"control.":[262],"Toxicity":[263],"levels":[266],"monitored":[268],"during":[269],"Exploratory":[271],"analyses":[272],"include":[273],"quantification":[274],"circulating":[276,292],"cells,":[278],"evaluation":[279,286],"vivo":[284],"predictive":[288],"genomic":[289],"biomarkers":[290],"DNA,":[294],"such":[295],"alterations":[297],"oncogenes":[299],"suppressors.":[302],"Citation":[303],"Format:":[304],"David":[305],"J.":[306],"Einstein,":[307],"Atish":[308],"Choudhury,":[309],"Philip":[310],"Saylor,":[311],"Lillian":[312],"Werner,":[313],"Mark":[314],"Erlander,":[315],"Maya":[316],"Ridinger,":[317],"Glenn":[318],"Bubley.":[319],"polo-like":[326],"kinase":[327],"(PLK1)":[328],"inhibitor":[329],"abiraterone":[334],"(abi)":[335],"metastatic":[341],"castration-resistant":[342],"(mCRPC)":[345],"[abstract].":[346],"In:":[347],"Proceedings":[348],"American":[351],"Association":[352],"for":[353],"Cancer":[354,368],"Research":[355],"Annual":[356],"Meeting":[357],"2019;":[358],"2019":[359],"Mar":[360],"29-Apr":[361],"3;":[362],"Atlanta,":[363],"GA.":[364],"Philadelphia":[365],"(PA):":[366],"AACR;":[367],"Res":[369],"2019;79(13":[370],"Suppl):Abstract":[371],"nr":[372],"CT161.":[373]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-09-23T05:00:35.095934","created_date":"2019-07-12T00:00:00"}